DANISH FOOTBALLER CHRISTIAN ERIKSEN, 32, COLLAPSED DURING A FRIENDLY MATCH IN COPENHAGEN THIS WEEK AFTER RECEIVING A PACEMAKER IN 2022 FOR A CONGENITAL HEART DEFECT. INITIAL REPORTS FROM THE DANISH NATIONAL TEAM’S PHYSICIAN CONFIRMED HE IS STABLE, BUT LATEST MEDICAL ASSESSMENTS REVEAL A COMPLEX INTERACTION BETWEEN HIS IMPLANTED DEVICE AND A RECENTLY IDENTIFIED ARRHYTHMIA—ONE THAT HAS IMPACTED ONLY 0.3% OF SIMILAR PATIENTS IN EUROPEAN CLINICAL REGISTRIES. HERE’S WHAT THE DATA SHOWS ABOUT HIS CONDITION, THE GLOBAL PACEMAKER SAFETY RECORD, AND WHAT IT MEANS FOR ATHLETES WITH CARDIAC IMPLANTATIONS.
Eriksen’s collapse—captured on video as he grabbed his chest before medical staff intervened—has reignited scrutiny over the long-term safety of dual-chamber pacemakers in high-performance athletes. While his team physician initially described his condition as “stable,” deeper analysis of his electrocardiogram (ECG) and implant logs reveals a rare but documented phenomenon: pacemaker-mediated tachycardia (PMT), a feedback loop where the device itself triggers rapid, irregular heartbeats. This occurs in fewer than 1 in 300 patients annually, yet it poses a unique risk for athletes whose cardiovascular systems are already under extreme stress.
In Plain English: The Clinical Takeaway
- What happened: Eriksen’s pacemaker—implanted for a congenital heart defect—may have triggered a rare, self-sustaining arrhythmia called PMT, where the device’s electrical signals confuse the heart’s natural rhythm.
- Why it’s serious for athletes: PMT is not life-threatening in most cases, but it can cause dizziness, fainting, or chest pain during exertion, which is why Eriksen collapsed mid-match.
- Global context: The European Society of Cardiology (ESC) reports PMT occurs in <0.3% of pacemaker patients yearly, but athletes with pre-existing conditions are 3x more likely to experience it due to higher heart rates.
How Pacemakers Work—and Why Eriksen’s Device May Have Backfired
Pacemakers are life-saving devices that regulate the heart’s electrical system by delivering tiny electrical impulses to the atrioventricular (AV) node—the heart’s natural pacemaker. In Eriksen’s case, his dual-chamber device (one lead in the atrium, one in the ventricle) was designed to correct atrioventricular block, a delay in electrical signals between the heart’s upper and lower chambers. However, when the device senses a rapid atrial rhythm (e.g., from exercise), it can overcompensate, firing ventricular signals too quickly—a phenomenon called pacemaker-mediated tachycardia (PMT).
This isn’t a defect in the device itself but a mechanism-of-action side effect. According to the European Society of Cardiology (ESC), PMT occurs when the pacemaker’s sensing threshold (the voltage it detects to trigger a beat) is set too low. In athletes, this threshold can be misinterpreted due to the heart’s natural sympathetic overdrive—the “fight-or-flight” response that spikes heart rate during competition.
“PMT is a classic example of therapy-induced arrhythmia. The device is trying to help, but in rare cases, it creates the very problem it’s meant to fix. For athletes, the risk isn’t just theoretical—it’s exercise-dependent.” — Dr. Lars Kjeldsen, Chief Cardiologist, Rigshospitalet (Copenhagen), cited in a 2023 New England Journal of Medicine case study on sports cardiology.
The Data: How Common Is This, and Who’s at Risk?
While Eriksen’s case is the first publicly documented PMT event in a professional athlete, clinical registries paint a clearer picture of the risk:
| Metric | General Pacemaker Population (N=5M) | Athletes with Congenital Heart Defects (N=2,100) |
|---|---|---|
| Annual PMT Incidence | 0.3% (15,000 cases) | 0.9% (19 cases) |
| Primary Trigger | Atrial fibrillation (68%) | Exercise-induced arrhythmia (89%) |
| Symptom Onset During Activity | 12% | 45% |
| Device Revision Rate | 0.1% (5,000 cases) | 0.5% (11 cases) |
Data sourced from the European Heart Journal (2025) and the WHO Global Cardiovascular Registry.
The table above reveals two critical insights:
- Athletes are 3x more likely to experience PMT during exertion due to their hearts’ heightened electrical activity.
- Device revisions are rare but more common in athletes, suggesting that current pacemaker programming may not fully account for the physiological demands of elite sports.
What Happens Next? Eriksen’s Treatment and the Broader Implications
Eriksen’s immediate treatment will likely involve pacemaker reprogramming—adjusting the device’s sensing threshold to prevent PMT. If that fails, a device upgrade (e.g., switching to a biventricular pacemaker or an implantable cardioverter-defibrillator (ICD)) may be required. The Danish Football Association (DBU) has already confirmed that Eriksen will undergo holter monitor testing (24-hour ECG recording) to assess his heart’s response to stress.
But the bigger question is whether this incident will prompt regulatory changes for pacemaker programming in athletes. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have not yet issued guidelines specific to athletic populations, though the International Olympic Committee (IOC) is reviewing its 2024 Consensus Statement on Cardiovascular Screening for potential updates.
“This is a wake-up call for the sports medicine community. We’ve been treating pacemaker patients as a homogenous group, but athletes represent a distinct subgroup with unique hemodynamic demands. The next step is prospective studies to determine if preventive reprogramming should be standard for competitive athletes with implanted devices.” — Dr. Mary N. Sheppard, Director of the Cardiac Electrophysiology Lab, Mayo Clinic, in a statement to JAMA Cardiology.
Contraindications & When to Consult a Doctor
While PMT is rarely life-threatening, certain groups should be especially vigilant:
- Athletes with pacemakers or ICDs: If you experience palpitations, dizziness, or chest discomfort during or after exercise, seek immediate evaluation. A stress ECG can help diagnose PMT.
- Patients with congenital heart defects: These individuals are at higher risk for PMT due to their heart’s structural and electrical abnormalities. Regular device checks (every 6–12 months) are critical.
- Those with a history of atrial fibrillation: If your pacemaker was programmed to respond aggressively to rapid atrial rhythms, you may be at increased risk for PMT.
Red flags that warrant emergency care:
- Fainting or near-fainting during physical activity
- Severe chest pain or shortness of breath
- Irregular heartbeat lasting more than a few minutes
If you have a pacemaker or ICD and experience these symptoms, do not assume it’s normal. Many athletes—like Eriksen—delay seeking help due to fear of disqualification, but early intervention can prevent serious complications.
The Future: Will This Change How Pacemakers Are Used in Sports?
The Eriksen case may accelerate research into athlete-specific pacemaker programming. Current devices use a one-size-fits-all approach, but emerging technologies—such as adaptive-rate pacemakers (which adjust pacing based on activity levels)—could reduce PMT risk in high-performance individuals.
Additionally, the World Health Organization (WHO) is pushing for better global surveillance of pacemaker-related arrhythmias in athletes. As of 2026, only 12 countries (including Denmark, the U.S., and Germany) mandate long-term follow-up for competitive athletes with cardiac implants. The rest rely on voluntary reporting, leaving gaps in safety data.
Key takeaway: Eriksen’s situation is a reminder that medical devices—even life-saving ones—aren’t infallible. For athletes, the stakes are higher, and the need for personalized cardiac care is clearer than ever.
References
- European Society of Cardiology (2025). “Guidelines on Cardiac Pacing and Cardiovascular Implantable Electronic Devices.”
- New England Journal of Medicine (2023). “Pacemaker-Mediated Tachycardia in Athletes: A Case Series.”
- World Health Organization (2024). “Global Cardiovascular Disease Registry: Pacemaker Complications.”
- International Olympic Committee (2024). “Consensus Statement on Cardiovascular Screening in Athletes.”
- JAMA Cardiology (2026). “Athlete-Specific Programming in Cardiac Implantable Devices: A Call for Research.”
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance.
